Peer Review

Eli Lilly’s CFO retiring after 27 years at company; Alexion names a new slate of execs

→  Mina Sooch has resigned as president, CEO, and director of Gemphire, citing “personal reasons.” The company has struggled financially and its drug candidate, gemcabene, in-licensed from Pfizer, has experienced roadblocks that are preventing it from being developed. Pfizer has the right to get the drug back if Gemphire does not succeed in commercializing it. Board member Dr. Steven Gullans will fill the role of president and CEO until the company finds a replacement.

→ After announcing a clean sweep of the executive suite a few days ago, Alexion has appointed John Orloff   executive vice president, head of research & development, Anne-Marie Law as executive vice president, chief human resources officer, and Indrani Lall Franchini to the position of executive vice president, chief compliance officer.

Derica Rice

→  Derica Rice, executive vice president global services and chief financial officer, will retire at the end of the year, after 27 years in various positions at Eli Lilly. The company is looking for his replacement.

→  Kunwar Shailubhai, has left Synergy as chief scientific officer. He had been there since 2004 in this role and as senior vice president of drug discovery. Rasna Therapeutics announced his appointment as CEO in April.

→  Financially-troubled MannKind elevated Michael Castanga from chief commercial officer to CEO.

→ Momenta Pharmaceuticals named Santiago Arroyo as CMO and senior vice president of development. He arrives by way of Pfizer and Boston Pharmaceuticals.

→ Generex Biotechnology terminated Andrew Greene as chief commercial officer, according to a filing with the SEC.

 


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy




EvaluatePharma World Preview 2017